R
Rock Springs Capital Management LP
+ HoldingPBLS
+18.51%
3M Return
$39.110
-0.180 (-0.46%)Zum Schluss
Loading chart…
- High
- 40.020
- Open
- 38.960
- VWAP
- 39.21
- Vol
- 316.25K
- Mkt Cap
- —
- Low
- 38.500
- Amount
- 12.40M
- EV/EBITDA, TTM
- -3.34
Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. It is built to develop transformative medicines addressing undruggable protein targets driving human disease. It leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides the Helicon approach and includes programs targeting two drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). The Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates.
AI analysis of Parabilis Medicines Inc (PBLS)
buyParabilis Medicines Inc is a good buy right now due to its recent price of $39.11, which is below the analyst price targets of $40 to $45, indicating potential upside. The company has shown a remarkable year-to-date change of +95.55%, signaling strong momentum. Additionally, the RSI is at 57.726, suggesting that the stock is not overbought yet. However, the main risk is the negative earnings report with an EPS of -2.13, which reflects ongoing losses, but the gross margin of 100% in the latest quarter indicates potential for future profitability as revenues grow.
Bewertungskennzahlen
The current forward P/E ratio for Parabilis Medicines Inc (PBLS) is 0.00, compared to its 5-year average forward P/E of .
Whales holding PBLS
Event-Zeitleiste
News
PBLS FAQ — answered by Alphio AI
Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. It is built to develop transformative medicines addressing undruggable protein targets driving human disease. It leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides the Helicon approach and includes programs targeting two drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). The Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates. It operates in the Healthcare sector.
Parabilis Medicines Inc is a good buy right now due to its recent price of $39.11, which is below the analyst price targets of $40 to $45, indicating potential upside. The company has shown a remarkable year-to-date change of +95.55%, signaling strong momentum. Additionally, the RSI is at 57.726, suggesting that the stock is not overbought yet. However, the main risk is the negative earnings report with an EPS of -2.13, which reflects ongoing losses, but the gross margin of 100% in the latest quarter indicates potential for future profitability as revenues grow.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.